ERBB2 and breast cancer: Previous studies that used population-based data have reported that young BC patients have higher rates of advanced, poorly differentiated tumors, estrogen receptor (ER) negativity, progesterone receptor (PR) negativity, human epidermal growth factor receptor 2 (HER-2) positivity, a higher Ki-67 index, and lymphovascular invasion [7-12].